Introduction
The basal level of NMDA receptor (NMDAR) activity can be considered to serve as the "set point" for the control of synaptic plasticity. The activity of these receptors is regulated by cell signals converging from a variety of G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases . In schizophrenia and attention deficit hyperactivity disorder, NMDAR activity may be too low Wong and Van Tol, 2003; Harrison and Weinberger, 2005) , and some GPCRs could be therapeutic targets for enhancing NMDAR activity (Marino and Conn, 2002a,b; Conn, 2003) . For example, the atypical agent clozipine may act via D 1 subtype dopamine receptor to potentiate NMDARmediated transmission via an Src-dependent mechanism (Wittmann et al., 2005) .
The late components of long-term potentiation (LTP) in the CA1 region require the cAMP-dependent signal cascade, protein kinase A (PKA) activity, the cAMP-response element-binding protein, and alterations in protein expression (Nguyen and Woo, 2003) . The pituitary adenylate cyclase activating peptide (PACAP) receptor is best known for its ability to stimulate adenylate cyclases, cAMP production, and PKA (Ohtaki et al., 1993; McCulloch et al., 2002) but also signals through G q/11 to phospholipase C (PLC) (Spengler et al., 1993; McCulloch et al., 2002) . PACAP1 receptors (PAC 1 Rs), specific for PACAP, are expressed predominantly in the brain, whereas VPAC receptors, which bind both VIP and PACAP, are more common in the periphery (Hashimoto et al., 1993) . PACAP ligand and the PAC 1 R are found in the CA1 region of the hippocampus (Shioda et al., 1998; Skoglosa et al., 1999; Zhou et al., 2000a,b) . PACAP stimulates both PKA and protein kinase C (PKC)-dependent signaling pathways (Zhou et al., 2001) , suggesting a potential role for PACAP in this region of the hippocampus. Indeed, low concentrations of PACAP potentiate NMDAR-mediated responses in CA1 neurons (Yaka et al., 2003) and modulate LTP in the hippocampus (Matsuyama et al., 2003) . Furthermore, transgenic mice lacking either PACAP or its major receptor (PAC 1 R) display disturbances in memory retention and consolidation (Yamamoto et al., 1998; Hashimoto et al., 2002; Matsuyama et al., 2003; Shintani et al., 2004) . The cellular mechanism of the acute PACAP-induced en-hancement of NMDAR responses has been attributed to activation of the cAMP cascade (Yaka et al., 2003) . In this model, Fyn is bound to receptor for activated C kinase-1 (RACK1), and PKAdependent phosphorylation releases Fyn, allowing it to phosphorylate NMDARs (Yaka et al., 2003) . This signaling by PACAP receptors contrasts with other GPCRs, which couple to G␣ q proteins [muscarine M 1 , metabotropic glutamate receptor subtype 5 (mGluR5), and lysophosphatidic acid (LPA)], to increase NMDAR activity and EPSC NMDA s in cultured, acutely isolated and in situ slice hippocampal CA1 neurons (Lu et al., 1999; Huang et al., 2001; MacDonald et al., 2001; Benquet et al., 2002; Gerber, 2002; Grishin et al., 2005 ) via a sequential signal network composed of PLC, PKC, Ca 2ϩ , cell adhesion kinase ␤ (CAK␤), or proline-rich tyrosine kinase 2 (Pyk2)/Src. The induction of LTP at CA1 synapses also requires activation of CAK␤(Pyk2)/Src (Huang et al., 2001 ).
Here we show that the major PACAP ligand, PACAP38, activates PAC 1 R to increase NMDA-evoked currents, and, although both G␣ s and G␣ q signaling pathways can be activated by PAC 1 Rs, it is the G␣ q pathway that is responsible for the enhancement of synaptic and peak NMDAR-mediated currents in CA1 neurons.
Materials and Methods
Cell isolation and whole-cell recordings. CA1 neurons were isolated from postnatal rats (Wistar, (14) (15) (16) (17) (18) (19) (20) (21) (22) or postnatal mice (28 -34 d) using previously described procedures (Wang and MacDonald, 1995) . To control for variation in response, recordings from control and treated cells were made on the same day. The extracellular solution consisted of the following (in mM): 140 NaCl, 1.3 CaCl 2 , 5 KCl, 25 HEPES, 33 glucose, and 0.0005 tetrodotoxin, pH 7.4 (osmolarity between 315 and 325 mOsm). Recording electrodes with resistances of 3-5 M⍀ were constructed from borosilicate glass (1.5 m diameter; World Precision Instruments, Sarasota, FL) using a two-stage puller (PP83; Narishige, Tokyo, Japan) and filled with intracellular solution containing the following (in mM): 140 CsF, 11 EGTA, 1 CaCl 2 , 2 MgCl 2 , 10 HEPES, 2 tetraethylammonium, and 2 K 2 ATP, pH 7.2 (osmolarity between 290 and 300 mOsm). Some drugs were included in the patch pipette. Recordings were conducted at room temperature (20 -22°C). After formation of the whole-cell configuration, the neurons were voltage clamped at Ϫ60 mV and lifted into the stream of solution supplied by a computer-controlled, multi-barreled perfusion system. To monitor access resistance, a voltage step of Ϫ10 mV was made before each application of NMDA. When series resistance varied by Ͼ10%, the cell was discarded. Currents were recorded using Axopatch 1D and 200 amplifiers (Axon Instruments, Union City, CA), and data were filtered at 2 kHz and acquired using Clampex (Axon Instruments). All population data are expressed as mean Ϯ SE. Student's t test was used to compare between two groups, and the ANOVA test was used to analyze multiple groups.
Recordings of miniature EPSC. Procedures for the preparation of mouse primary dissociated cultures of hippocampal neurons have been described previously (MacDonald et al., 1989) . Two to 3 weeks after plating, pyramidal cells were selected for whole-cell recordings (temperature, 20 -22°C) . The series resistance in these recording varied between 6 and 8 M⍀, and recordings in which series resistance varied by Ͼ10% were rejected. No electronic compensation for capacitance or series resistance was applied. All solutions were the same as for isolated cells, except the extracellular solution also contained 10 M bicuculline to inhibit GABA-mediated chloride conductance. At the holding potential of Ϫ60 mV, miniature EPSCs (mEPSCs) were recorded for 5 min both in the absence and presence of 10 M ␣-amino-5-phosphonopentanoic acid (APV) before and 10 min after PACAP (1 nM) application. All mEPSCs were manually selected and averaged using Mini Analysis software (Synaptosoft, Decatur, GA). The NMDA component was obtained by subtracting the averaged mEPSC in the presence of APV from that in its absence. The amplitude of the NMDA component under control conditions and after PACAP application was compared.
Hippocampal slice preparation and recording. Hippocampal brain slices were prepared from 14-to 21-d-old Wistar rats. Briefly rats were decapitated after halothane anesthesia, and brains were quickly removed and placed in ice-cold oxygenated (95% O 2 , 5% CO 2 ) artificial CSF (aCSF) [in mM: 124.0 NaCl, 3.0 KCl, 1.3 MgCl 2 ⅐6H 2 O, 2.6 CaCl 2 , 1.25 NaH 2 PO 4 ⅐H 2 O, 26 NaHCO 3 , 10.0 D-glucose (osmolarity between 300 and 310 mOsm)]. Whole-brain coronal slices (300 m) containing transverse sections of the hippocampus were prepared using a vibratome (VT100E; Leica, Nussloch, Germany). After a recovery period of 1 h in oxygenated aCSF, tissues were transferred to a recording chamber mounted on the stage of an upright microscope (BX51WI; Olympus Optical, Tokyo, Japan) equipped with a water immersion objective (40ϫ; numerical aperture, 0.95; working distance, 2.0 mm), Nomarski optics, and infrared-differential interference contrast video microscopy. The CA1 region was isolated from CA3 with a surgical cut, and slices were continually perfused with 0 Mg 2ϩ oxygenated aCSF (2-3 ml/min) at room temperature (22-24°C). Tight seals (Ͼ1 G⍀) were formed on the cell body of visually identified CA1 pyramidal neurons, and whole-cell voltage-clamp recordings were obtained by rupturing the membrane with negative pressure. Recording electrodes as described previously were filled with an internal solution containing the following (in mM): 140 Cs-gluconate, 11 EGTA, 10 HEPES, and 2 MgCl 2 , pH 7.2-7.3. Cells were held at Ϫ60 mV, and series resistance was monitored throughout the recording period. Only recordings with stable holding current and series resistance maintained below 30 M⍀ were considered for analysis. Schaffer collateral synapses were stimulated every 30 s with constant current pulses (50 -100 s) delivered through a concentric bipolar platinum stimulating electrode (25 m exposed tip) positioned at the border of stratum radiatum-stratum lacunosum. Evoked EPSC NMDA s were isolated by the addition of CNQX (20 M) and bicuculline (10 M). Electrode placement and intensity were contingent on evoking the largest NMDA response without eliciting an action potential or spiking artifact. PACAP was applied after 5 min of a stable baseline period, and EPSCs were recorded for the subsequent 15 min. Excitatory synaptic currents were recorded using a Multiclamp 700A amplifier (Axon Instruments), low-pass filtered at 2 kHz, and digitized at 10 -20 kHz with Clamplex (version 9.2; Axon Instruments).
Membrane adenylyl cyclase assay. Hippocampal tissue from wild-type or PLC␤1-null mice was Dounce homogenized on ice in 1 ml of ice-cold buffer (15 mM HEPES, pH 7.4, 5 mM MgCl 2 , 2 mM EDTA, 1 mM 3-isobutyl-1-methylxanthine, and 0.01% ascorbic acid). Approximately 40 g of tissue homogenate was incubated with drugs and reaction mixture (2 mM ATP, 5 M GTP, 20 mM phosphocreatine, and 5 U of creatine phospho-kinase) at 30°C for 15 min. The reaction was terminated by the addition of 100 l of ice-cold 4% trichloroacetic acid. cAMP levels were determined using the BTI cAMP radioimmunoassay system (Biomedical Technologies, Stoughton, MA) according to the instructions of the manufacturer. Briefly, samples were incubated overnight with a known amount of 125 I 2Ј-0-succinyl-cAMP and a cAMP binding antibody. After incubation, samples were mixed with 1 ml of ice-cold buffer (50 mM sodium acetate and 0.01% sodium azide, pH 7.4) and centrifuged at 2000 ϫ g for 20 min. The supernatant was decanted, and the radioactivity level bound to the antibody was determined.
Tyrosine phosphorylation of Src. The CA1 region from acute hippocampal slices from Wistar rats (14 -21 d) was microdissected and allowed to recover for 2 h at room temperature (20 -22°C). The CA1 region of multiple animals was pooled to provide sufficient tissue for the assay. Twenty minutes before stimulation with agonist, the tissue was transferred to extracellular fluid that containing sodium vanadate (10 M), treated at room temperature, and then immediately frozen on dry ice. Tissue was then homogenized in ice-cold lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% NP-40, 1 mM sodium orthovanadate, and the protease inhibitors pepstatin A (20 g/ml), leupeptin (20 g/ml), and sprotinin (20 g/ml). Insoluble material was removed by centrifugation at 14,000 ϫ g for 10 min at 4°C. The protein content of soluble material was determined by Bio-Rad (Hercules, CA) Dc protein assay. Soluble proteins (1000 g) were incubated overnight with 8 l of anti-Src GD 11 (Upstate Biotechnology, Lake Placid, NY). Immune complexes were isolated by the addition of 20 l of protein A Sepharose beads, followed by incubation for 1 h at 4°C. Immunoprecipitates were washed four times with lysis buffer. Samples were subjected to SDS-PAGE using a 10% gel transferred to a nitrocellulose membrane. Membranes were immunoblotted with monoclonal antibodies to phosphorylated tyrosine, 4G10 (1:1000 dilution; Upstate Biotechnology), or Src tyrosine 416 (provided by Dr. M. W. Salter, Hospital for Sick Children, Toronto, Ontario, Canada) or Src tyrosine 457. Membranes were then stripped and probed for total Src using anti-Src. Signals were detected with enhanced chemiluminescence (Amersham Biosciences, Arlington Heights, IL) and developed on x-ray film. Band intensity on x-ray film was quantified. For phospho-Src, the intensity of the phosphorylated signal was divided by that of total Src to control for small differences in gel loading. Experimental and control conditions were then compared and expressed as percentage of control.
Animals. All animal experimentation was conducted in accordance with the Policies on the Use of Animals at the University of Toronto. PLC␤1 wild-type and knock-out animals were provided by Dr. John Roder (Mount Sinai Hospital, Toronto, Ontario, Canada).
Drugs and peptides. The source of drugs for this study are as follows: NMDA and glycine (Sigma, St. Louis, MO), PACAP38, bisindolylmaleimide I (bis), BAPTA (Calbiochem, La Jolla, CA), PACAP(6 -38) (Phoenix Pharmaceuticals, Mountain View, CA), and Src(p60 c-Src ) (Upstate Biotechnology). CAK␤, CAK␤ 457A, and Src(40 -58) were provided by Dr. M. W. Salter. Peptides were synthesized by the Advanced Protein Technology Centre (Toronto, Ontario, Canada) with the following sequences: R1 (SRDKTIIMWKLTRD, RACK1 amino acids 35-48) and R6 (DLNEGKHLpYTL-DGGDIINALCFSPNRpYWL, RACK1 amino acids 220 -248).
Results
Initially, the ability of low concentrations of PACAP38 (1 nM) to modulate EPSC NMDA s at CA1 synapses was studied. Pyramidal neurons were patch clamped in a whole-cell configuration and held at Ϫ60 mV. Schaffer collateral fibers were stimulated every 30 s with constant current pulses (50 -100 s) to evoke EPSC NMDA s. Applications of PACAP38 to these slices caused an increase in the peak amplitude of NMDA synaptic currents ( Fig.  1 ). This enhancement reached a plateau that was 167 Ϯ 10% (n ϭ 6) above baseline values. We had previously observed a similar potentiation of NMDA-evoked peak currents in isolated CA1 neurons after activation of several G␣ q signaling pathways, including the mGluR5, the M 1 muscarinic, and LPA receptors. These receptors enhance NMDARs via a sequential G␣ q -PLC␤-PKC-CAK␤(Pyk2)/Src signal cascade (Lu et al., 1999; , and we hypothesized that PAC 1 Rs might also activate this cascade. The final downstream enzyme in this cascade is Src. Therefore, we recorded EPSC NMDA s using patch electrodes containing the Src inhibitory peptide Src(40 -58) (25 g/ml). This Src-specific inhibitory peptide mimics the unique domain of Src but not Fyn. Src(40 -58) eliminated the PACAP38-induced potentiation of these synaptic currents, illustrating that PACAP38 causes a change in NMDA synaptic activity that is mediated by Src and not by Fyn.
To further elucidate the signaling pathway responsible for this effect, we acutely isolated individual CA1 pyramidal cells from the slices. Slice recordings are restricted in that drugs applied to the slice must permeate the tissue to exert a response at the recorded cell. Variation between slices in the depth of the recorded cell could alter the effective drug concentration at the cell. Use of acutely isolated cells avoids this restriction. In addition, isolated neurons permit a rapid application of agonist, allowing for the resolution of both peak and steady-state NMDAR currents. Furthermore, we have shown that peak currents and EPSC NMDA s are modulated in parallel by a variety of GPCRs and growth factor receptor .
To examine the effects of PACAP38 on NMDAR-mediated currents, PACAP38 was applied to isolated CA1 hippocampal neurons continuously for 5 min. NMDA currents were evoked once every 60 s using a 3 s exposure to NMDA (50 M) and glycine (0.5 M). Applications of PACAP38 (1 nM) produced a rapid and robust increase in NMDA-evoked currents (Fig. 2 A) . This effect outlasted the application period of PACAP38 and reached a plateau ϳ10 min after PACAP38 application. The increase in normalized peak currents after 20 min after PACAP application was 140 Ϯ 5% (n ϭ 9) compared with baseline (100%). NMDA-evoked currents were stable over the recording period, with control cells having normalized peak currents 98 Ϯ 7% (n ϭ 9) of baseline ( Fig. 2 A) . The effect of PACAP38 could be seen most clearly in the peak of the NMDA-evoked current (Fig.  2 B) . No significant changes were seen in time constants () for activation, desensitization, or inactivation phases of the recording before, during, or after PACAP38 application (data not shown). PACAP38 has been reported previously to induce enhancement of field excitatory synaptic potentials with low con- Figure 1 . PACAP38 enhances NMDA currents in hippocampal slice. A, Application of 1 nM PACAP38 to hippocampal slices caused increased amplitude in NMDA currents. Pyramidal cells were recorded in a whole-cell configuration. NMDA peak currents reached a maximal increase ϳ8 min after application. Normalized peak amplitude for PACAP-treated cells was 167 Ϯ 10% compared with baseline (n ϭ 6). When Src(40 -58) (25 g/ml) was included in the patch pipette, PACAP38 failed to elicit a response [normalized peak current, 102 Ϯ 2% (n ϭ 6); p Ͻ 0.005, unpaired t test; data obtained at 20 min of recording]. The black bar indicates time and duration of 1 nM PACAP38 application. B, Sample traces from individual cells with and without Src(40 -58) in the patch pipette at baseline (t ϭ 0 min) and after PACAP38 application (t ϭ 20 min).
centrations but depression with higher concentrations (Roberto and Brunelli, 2000) . A range of concentrations of PACAP38 were tested to ensure that the concentrations used reliably produced positive modulation without being close to the range of negative modulation. At all concentrations up to and including 10 nM, PACAP38 enhanced peak NMDA currents (Fig. 2C) .
It has also been proposed that PACAP38 interacts directly with NMDARs to potentiate their activity, perhaps by binding to the glycine site of the NMDAR (Liu and Madsen, 1997) . We examined potential direct effects using a protocol whereby PACAP38 was applied during the simultaneous application of NMDA and glycine. Briefly, NMDA (and glycine) was applied using one barrel.
Once the response reached a steady state, the barrel was shifted to one containing NMDA (glycine) and PACAP38 for a period of 3 s before returning to the barrel lacking PACAP38. Rapid effects of PACAP38 was assessed as a change in the steady-state current. No rapid effects were observed with concentrations of 1-10 nM PACAP38. However, when the concentration was increased to 100 nM, a depression of currents was observed (Fig. 2 D, F ). This depression recovered entirely within 10 s of the application of PACAP38 and likely reflects a direct inhibition of NMDARs. This rapid inhibition, measured as the percentage of decrease in steady-state currents compared with control, did not differ in low (0.1 M) or high (10 M) concentrations of glycine (Fig. 2 E) . This suggests that the inhibition displayed by PACAP38 was not related to the glycine binding site on the NMDAR. Because the 1 nM concentration of PACAP38 produced the greatest enhancement of NMDAR peak currents and had no direct inhibitory effect, this concentration was used throughout the remaining experiments. To confirm that PACAP38 was signaling via activation of the G-proteincoupled PAC 1 receptors, we used PACAP(6 -38), the most potent antagonist for PAC 1 receptors (Robberecht et al., 1992) . Coapplications of PACAP(6 -38) (10 nM) substantially attenuated the PACAP38 effect (Fig. 3A) . When the antagonist was present, PACAP38 (1 nM) induced only a moderate (113 Ϯ 5%; n ϭ 6) increase in NMDA-evoked currents relative to controls (141 Ϯ 8%; n ϭ 6). Although the PAC 1 receptor was required for the PACAP38 effect, the possibility exists that signaling is not mediated via G-proteins because not all GPCR signaling requires heterotrimeric G-proteins (Hall et al., 1999) . To ensure that the PACAP38 effect required signaling through G-proteins, GDP-␤-S a competitive inhibitor for the GTP binding site on the ␣ subunit, was included in the patch pipette. Inclusion of 20 M GDP-␤-S blocked the PACAP38-mediated increase in NMDA-evoked currents. Without inclusion of GDP-␤-S in the patch pipette, PACAP38 (1 nM) increased NMDA-evoked currents (41 Ϯ 7%; n ϭ 7) above baseline (Fig. 3B) . When GDP-␤-S was included in the patch pipette, NMDA-evoked currents were 96 Ϯ 2% (n ϭ 5) of baseline (Fig. 3B) . As a control, we showed Figure 2. PACAP38 enhances peak currents in isolated CA1 pyramidal neurons. A, Application of PACAP38 (1 nM) to acutely isolated CA1 pyramidal neurons resulted in an increase of NMDA-evoked peak currents that outlasted the period of application, did not reverse during washout, and persisted throughout the recording period. NMDA-evoked peak currents in control cells were unchanged throughout the time course of the experiment. Cells treated with 1 nM PACAP38 had significantly larger NMDA-evoked peak currents (control, 98 Ϯ 7%, n ϭ 9; 1 nM PACAP38, 140 Ϯ 5%, n ϭ 9; p Ͻ 0.001, unpaired t test; data obtained at 20 min of recording). The black bar indicates time and duration of 1 nM PACAP38 application. B, Sample traces of NMDA-evoked currents for control and PACAP38-treated cells. Traces represent points immediately before PACAP38 application (t ϭ 5 min) and 10 min after PACAP38 application (t ϭ 20 min). C, PACAP38 modulation of NMDA peak currents was dose dependent. Change from baseline: control, Ϫ1 Ϯ 7%, n ϭ 9; 1 pM, 16 Ϯ 6%, n ϭ 4; 10 pM, 23 Ϯ 5%, n ϭ 5; 100 pM, 35 Ϯ 7%, n ϭ 5; 1 nM, 44 Ϯ 5%, n ϭ 9; 10 nM, 37 Ϯ 13%, n ϭ 6; data obtained at 20 min of recording. *p Ͻ 0.05, **p Ͻ 0.001 versus control, ANOVA followed by post hoc Tukey's test. D, PACAP38 at 100 nM directly inhibits NMDA currents. Sample traces from the same cell are shown without 100 nM PACAP38 application (black trace) and with 100 nM PACAP38 application (gray trace) during middle 3 s of NMDA-evoked current. Inhibition by PACAP38 was measured as the percentage that the steady-state decreased. E, Inhibition by 100 nM PACAP was not altered by the concentration of glycine. PACAP38 at 100 nM caused equal levels of inhibition in 0.1 and 10 M glycine (low glycine, 29 Ϯ 4%, n ϭ 6; high glycine, 27 Ϯ 4%, n ϭ 6; p Ͼ 0.3, unpaired t test). F, NMDA currents were only inhibited by 100 nM PACAP38. With doses from 1 pM to 100 nM, only 100 nM PACAP38 showed a significant inhibition of NMDA currents (ANOVA followed by post hoc Tukey's test, p Ͻ 0.05).
that GDP-␤-S itself had no effect on NMDA-evoked currents (Fig. 3B) . Because PAC 1 Rs can signal through G␣ q/11 G-proteins to PLC (Zhou et al., 2001 ) and because PLC-mediated pathways are involved in the modulation of NMDA currents (Skeberdis et al., 2001) , we decided to examine the role of PLC in the potentiation of NMDA-evoked currents by PACAP38.
For this reason, we examined CA1 neurons from PLC␤1 knock-out mice (Kim et al., 1997) . In PLC␤1 knock-out mice, the effect of PACAP38 (1 nM) was markedly attenuated (110 Ϯ 5%; n ϭ 14) compared with the effect in wild-type mice (144 Ϯ 8%; n ϭ 10) (Fig. 4 A) . Adenylyl cyclase (AC) activity assays were performed to control for the possibility that the reduced PACAP38 response was caused by a defect in the PAC1 receptor or in AC activity in the PLC␤1 knock-out mice (Fig. 4 B) . Compared with vehicle-treated tissue, PACAP38-treated hippocampal tissue from wild-type mice had a 1.8 Ϯ 0.3-fold (n ϭ 4) increase in AC activity. In tissue from PLC␤1 knock-out mice, PACAP induced a similar fold increase in AC activity (1.5 Ϯ 0.1-fold increase; n ϭ 4). The PKA activator forskolin (30 M) also induced a similar fold increase in both wild-type (6.0 Ϯ 1.3 fold increase; n ϭ 4) and knock-out (4.2 Ϯ 0.7-fold increase; n ϭ 4; p Ͼ 0.05) animals (Fig. 4 B) . A decrease in PACAP38 modulation in PLC␤1 knock-out mice, despite PACAP38 inducing the same level of AC activation as in wild-type mice, indicates that modulation by PACAP38 is predominantly mediated through PLC␤1 and not the activation of AC. The prototypical G␣ q signaling pathway activates PLC␤ and leads to the formation of inositol trisphosphate (IP 3 ) and diacylglycerol (DAG) (Neves et al., 2002) . IP 3 formation triggers Ca 2ϩ release from internal stores, which along with DAG, is required for activation of the conventional PKC isoforms (PKC␣, PKC␤I, PKC␤II, and PKC␥) (Liu and Heckman, 1998) . As such, we examined the role of calcium and PKC in mediating the PACAP38 effect.
Our patch pipette solution contains 11 mM EGTA, a Ca 2ϩ chelator with slow binding kinetics. As such, inclusion of 11 mM Figure 3 . Effect of PACAP38 on NMDA-evoked currents requires the G-protein-coupled PAC 1 receptor. A, Addition of 10 nM PACAP(6 -38), a potent antagonist of PACAP38 specific for the PAC 1 receptor, in all extracellular solutions for the duration of the experiment significantly attenuated the increase in NMDA-evoked currents by 1 nM PACAP38 (1 nM PACAP38, 141 Ϯ 8%, n ϭ 6; 10 nM PACAP(6 -38) plus 1 nM PACAP38, 113 Ϯ 5%, n ϭ 7; p Ͻ 0.05, unpaired t test; data obtained at 20 min of recording). The black bar indicates time and duration of 1 nM PACAP38 application. B, Increased NMDA-evoked peak currents are blocked by GDP-␤-S. Intracellular application of 20 M GDP-␤-S blocked the increase in NMDA-evoked peak currents by 1 nM PACAP38 (1 nM PACAP38, 141 Ϯ 7%, n ϭ 7; 1 nM PACAP38 plus 20 M GDP-␤-S, 96 Ϯ 2%, n ϭ 6; 20 M, p Ͻ 0.001, unpaired t test; data obtained at 20 min of recording). Comparatively, GDP-␤-S alone had no effect on NMDA-evoked currents (103 Ϯ 6% of baseline; n ϭ 5). The black bar indicates time and duration of 1 nM PACAP38 application. (1 nM) failed to elicit a response in PLC␤1 knock-out mice but produced a robust increase in NMDA-evoked peak currents in wild-type mice (wild-type mice, 144 Ϯ 8%, n ϭ 10; knock-out mice, 110 Ϯ 5%, n ϭ 14; p Ͻ 0.001, unpaired t test; data obtained at 20 min of recording). The black bar indicates time and duration of 1 nM PACAP38 application. B, Adenylyl cyclase activity was unchanged in PLC␤1 knock-out mice. Hippocampal tissue was extracted from wild-type or PLC␤1 knock-out mice, and tissue from three to five mice were pooled. Forskolin (30 M) induced a similar fold increase in both wild-type (6.0 Ϯ 1.3-fold increase; n ϭ 4) and knock-out (4.2 Ϯ 0.7-fold increase, n ϭ 4; p Ͼ 0.05, unpaired t test) animals. Compared with vehicle-treated tissue, PACAP38-treated hippocampal tissue from wild-type mice had a 1.8 Ϯ 0.3-fold (n ϭ 4) increase in AC activity. In hippocampal tissue from PLC␤ knock-out mice, PACAP induced a similar fold increase in AC activity (1.5 Ϯ 0.1-fold increase, n ϭ 4; p Ͼ 0.05, unpaired t test).
EGTA in the patch pipette could potentially reduce the Ca 2ϩ signal induced by PACAP application. However, in these conditions, a robust response by PACAP was seen, suggesting that, if Ca 2ϩ is required for this response, EGTA is not completely blocking Ca 2ϩ signaling. The amplification of the unbuffered Ca 2ϩ signal by downstream signaling molecules likely overcomes any reduction in the Ca 2ϩ signal by EGTA. Thus, to test whether the modulation of NMDA-evoked currents by PACAP38 required the elevation of internal Ca 2ϩ , we used high concentrations of the fast Ca 2ϩ chelator BAPTA (20 mM) in the patch pipette, which provides a more complete chelation of Ca 2ϩ compared with EGTA. Intracellular application of 20 mM BAPTA blocked the effect of 1 nM PACAP38 (Fig. 5A) . The application of BAPTA by itself caused no change in normalized peak NMDA currents over time. Calcium is an important signaling divalent cation that can act on many different Ca 2ϩ -activated enzymes and proteins. In the case of mGluR5 potentiation of NMDARs, there is a requirement for coincident activation of NMDARs and mGluRs; without coincident activation, depression of NMDA currents occurs . To determine whether coincident activation of NMDARs and PAC 1 Rs was required in PACAP-induced signaling, NMDA was not applied during the application of PACAP38. In the absence of coincident NMDAR activation, PACAP38 was still able to potentiate NMDA-evoked currents (Fig. 5B) . These observations indicated that coincident activation of NMDARs and PAC 1 Rs is not required for PACAP potentiation of NMDA currents.
To determine the role of PKC in the PACAP38 effect, we used the PKC inhibitor bisindolylmaleimide I (bis), which has affinity for PKC␣, PKC␤ I , PKC␤ II , PKC␥, PKC␦, and PKC⑀ isozymes. Applications of bis (500 nM) blocked the effect of PACAP38 (97 Ϯ 4%; n ϭ 6) but had no effect when applied alone (Fig. 5C ). These results demonstrate that the PLC␤1/PKC pathway is required for the PACAP38 modulation of NMDA-evoked currents and that the signaling pathway requires a rise in intracellular Ca 2ϩ . Protein kinase C can also activate proline-rich tyrosine kinase 2, also called cell adhesion kinase ␤ (Pyk2/CAK␤), which binds, activates, and phosphorylates Src, leading to enhanced NMDAR activity (Huang et al., 2001; . Because PKC appeared to be involved in the PACAP38 effect, we tested the possibility that CAK␤ is also required. Intracellular application of the functional dominantnegative mutant of CAK␤ (kinase mutant, CAK␤-K457A, 0.5 g/ml) exerted no effect on its own but blocked the PACAP38-induced potentiation of NMDA-evoked currents (Fig. 5D ). In addition, inclusion of recombinant CAK␤ (0.5 g/ml) in the patch pipette caused a potentiation of these currents that subsequently occluded the effect of PACAP38 (Fig. 5D ). G-protein-coupled receptors can recruit PKC signaling pathways that activate the nonreceptor tyrosine kinases CAK␤ (Dikic et al., 1996; Lu et al., 1999) . Furthermore, once CAK␤ is activated, the kinase autophosphorylates, creating an Src homology 2 (SH2) ligand that binds to the SH2 domain of Src, resulting in its activation (Dikic et al., 1996) . As such, we looked at the role Src may have in the PACAP38-mediated increase in NMDA-evoked currents. Application of 30 U/ml recombinant Src(p60 c-src ) caused a rapid increase in normalized NMDA-evoked peak currents (Fig. 6 A) . The effect reached a plateau at 10 min, with a 46 Ϯ 10% (n ϭ 6) increase above baseline. Applications of PACAP38 (1 nM) at this point failed to elicit an additional increase, with NMDA-evoked currents measured as a 53 Ϯ 8% (n ϭ 6) increase above baseline 10 min after PACAP38 application. Intracellular application of the Src inhibitory peptide Src(40 -58) completely blocked the effect of PACAP38 (Fig. 6 B) . By itself, Src(40 -58) had no effect on the amplitude of NMDA-evoked currents. Block of the PACAP38 effect by the Src inhibitor and occlusion by Src(p60 c-src ) support the involvement of Src in the PACAP38- (20 mM) blocked the PACAP38 effect and was similar to BAPTA alone (BAPTA plus PACAP38, 97 Ϯ 4%, n ϭ 6; BAPTA alone, 95 Ϯ 4%, n ϭ 6; p Ͼ 0.2, unpaired t test; data obtained at 20 min of recording; 1 nM PACAP38, 143 Ϯ 7%, n ϭ 6). The black bar indicates time and duration of 1 nM PACAP38 application. B, Blocking the entry of external calcium did not prevent PACAP-mediated enhancement of NMDA peak currents. To block external calcium entry, no NMDA was applied during the application of 1 nM PACAP38 (control, 98 Ϯ 9%, n ϭ 6; 1 nM PACAP38, 148 Ϯ 12%, n ϭ 5; p Ͻ 0.01, unpaired t test; data obtained at 20 min of recording). C, Protein kinase C is required for the PACAP38 response. Application of the PKC inhibitor bisindolylmaleimide I (500 nM) applied through internal and external solution blocked the effect of PACAP38 on NMDA-evoked currents and had no effect by itself (1 nM PACAP38, 130 Ϯ 4%, n ϭ 8; PACAP38 plus bisindolylmaleimide I, 103 Ϯ 5%, n ϭ 12; p Ͻ 0.005, unpaired t test; bisindolylmaleimide I alone, 97 Ϯ 2%, n ϭ 5). The black bar indicates time and duration of 1 nM PACAP38 application. D, Pyk2/CAK␤ is required for the PACAP38 response. Intracellular application of wild-type CAK␤ (0.5 g/ml) caused an increase in NMDA-evoked peak currents, reaching a plateau after 7 min. Five minute application of PACAP38 (1 nM) on top of the plateau caused no significant increase (CAK␤ before PACAP38, 142 Ϯ 8%, n ϭ 6; 5 min after PACAP38 application, 154 Ϯ 12%, n ϭ 6; p Ͼ 0.3, paired t test; data obtained at 10 and 25 min of recording). The PACAP38 response could be blocked by a kinase inactive mutant version of the enzyme (lysine 457 to alanine). Intracellular application of CAK␤ 457A (0.5 g/ml) blocked the effect of PACAP38 (1 nM) and was similar to CAK␤ 457A applied by itself (CAK␤ 457A plus 1 nM PACAP38, 103 Ϯ 3%, n ϭ 6; CAK␤ alone, 98 Ϯ 2%, n ϭ 5; data obtained at 20 min of recording; *p Ͻ 0.01 vs CAK␤ 457A and CAK␤ 457A plus 1 nM PACAP38, ANOVA followed by post hoc Tukey's test).
mediated effect on NMDA-evoked currents. To further substantiate the involvement of Src, phosphorylation levels of Src were measured. Because phosphorylation of tyrosine 416 is required for activation of the kinase (Smart et al., 1981) , increased phosphorylation can be used as a measure of its kinase activity. CA1 hippocampal tissue was microdissected and treated with PACAP38 or vehicle for 10 min at room temperature. Tissue was homogenized, and Src was immunoprecipitated with an antibody directed at the unique domain of Src. Subsequently blots were probed with an anti-phospho-tyrosine antibody. Phosphorylation levels were normalized to total Src. Treatment with PACAP38 increased Src phosphorylation in the CA1 region, as shown in the representative blot (Fig. 6C) . The normalized density of the Src blots was measured for three such experiments and compared with controltreated tissue. A 32 Ϯ 11% (n ϭ 3) increase in phosphorylation levels was seen (Fig. 6 D) . Src can be tyrosine phosphorylated on many sites, including tyrosine 416, which is required for activation, and tyrosine 527, which causes inactivation of the kinase (Smart et al., 1981) . To confirm that the increased tyrosine phosphorylation was activating Src, a second set of experiments was performed using sitespecific antibodies for tyrosine 416 and 527. An increase of 51% was seen at Y416, although no change in phosphorylation of Y527 was observed after treatment with PACAP38. These results confirm the results seen in experiments with hippocampal slices. To confirm that PACAP38 induces an Src-dependent potentiation of synaptic currents, we also examined spontaneous mEPSCs recorded in cultured mouse hippocampal neurons. Miniature EPSC NMDA s were recorded for 5 min in both the absence and presence of APV (10 M) before and after a 10 min application of PACAP38. PACAP enhanced the NMDAR component of mEPSCs by 45 Ϯ 16% (n ϭ 6) (Fig. 6 E) . Comparatively, the AMPA component of mEPSCs was unchanged by PACAP treatment (Fig. 6 E) . Inclusion of the selective Src kinase peptide inhibitor Src(40 -58) in the patch pipette completely blocked the modulatory effect of PACAP38 (fractional change, 2 Ϯ 13%; n ϭ 6) (Fig. 6 E) . Representative mEPSCs are shown for control, APV treated (i.e., AMPA component), and after PACAP38 application (Fig. 6 F) .
The tyrosine kinase Fyn has also been implicated in the enhancement of NMDARs by PACAP38 (Yaka et al., 2003) . This signaling pathway is believed to involve the release of Fyn kinase from the scaffolding protein RACK1. During release from RACK1, Fyn then phosphorylates the NR2B subunit, thus potentially increasing NMDAR activity (Yaka et al., 2003) . In addition to Fyn, RACK1 binds various signaling intermediates, including but not limited to PKC␤II (Ron and Mochly-Rosen, 1994) , PLC␥ (Disatnik et al., 1994) , and Src (Chang et al., 1998) . Sequestering of Fyn and Src kinases by RACK1 blocked the ability of these kinases to participate in cell signaling (Chang et al., 1998; Yaka et al., 2002) . The reported Fyn binding site on RACK1 is located in tryptophan-aspartate (WD) repeat 1 and includes amino acids 35-48 (Yaka et al., 2002) . Comparatively, the Src binding site on RACK1 is located in WD repeat 6, with phosphorylated tyrosines at positions 228 and 246 playing key roles in the degree of binding of Src (Chang et al., 2001 ). In the case of Fyn, introduction of a Figure 6 . Nonreceptor tyrosine kinase Src is required for PACAP38 modulation of NMDA currents. A, Inclusion of 30 U/ml p60 c-src in the intracellular solution caused a rapid and sustained increase in NMDA-evoked currents that occluded the effect of 1 nM PACAP38 (before PACAP38 application, 146 Ϯ 10%, n ϭ 6; 10 min after PACAP38 application, 153 Ϯ 8%, n ϭ 6; p Ͼ 0.5, paired t test; data obtained at 10 and 25 min of time recording). The black bar indicates time and duration of 1 nM PACAP38 application. B, Inclusion of the selective Src kinase peptide inhibitor Src(40 -58) at 25 g/ml in the patch pipette completely blocked the PACAP38 response (1 nM PACAP38, 132 Ϯ 8%, n ϭ 6; Src(40 -58) plus 1 nM PACAP38, 100 Ϯ 3%, n ϭ 8; p Ͻ 0.005, unpaired t test; data obtained at 20 min of recording). Inclusion of Src(40 -58) by itself had no effect alone, 97 Ϯ 4%, n ϭ 6; data obtained at 20 min of recording]. C, D, Activation of Src by 1 nM PACAP38 was determined by phosphorylation levels of Src. Microdissected CA1 hippocampal tissue was treated with vehicle or 1 nM PACAP38 for 10 min. Src was immunoprecipitated and probed with a phosphotyrosine antibody. Phosphorylation levels were normalized to the total amount of Src loaded and measured as a relative change compared with control. PACAP38 treatment increased tyrosine phosphorylation levels 32 Ϯ 11% (n ϭ 3) above vehicle-treated tissue. E, PACAP38 increased the NMDA component of mEPSPs, and the increase was Src dependent. Application of PACAP38 (1 nM) to cultured hippocampal neurons for 5 min increased the NMDA component of miniature EPSPs by 45 Ϯ 16% (n ϭ 6). Comparatively, the AMPA component of the mEPSPs was unchanged, with a fractional current modulation of Ϫ3 Ϯ 9% (n ϭ 6). Inclusion of the selective Src kinase peptide inhibitor Src(40 -58) at 25 g/ml in the patch pipette completely blocked the PACAP38 response (fractional change, 1.5 Ϯ 13%; n ϭ 5). F, Sample traces are shown for control, APV treated (i.e., AMPA component), and after PACAP38 treatment.
small peptide corresponding to the Fyn binding site in RACK1 disrupts the binding of RACK1 and Fyn and increases the ability of the kinase to signal (Yaka et al., 2002) . Therefore, to test the involvement of the scaffolding protein RACK1 in mediating the signaling pathway by PACAP, we synthesized two peptides, one corresponding to the Fyn binding site in WD repeat 1 (Yaka et al., 2002) and one corresponding to the Src binding site in WD repeat 6 (Chang et al., 2001 ), which we named R1 and R6, respectively. Inclusion of either peptide in the patch pipette at a concentration of 100 M caused an increase in evoked NMDA peak currents (Fig. 7 A, B) . The increase induced by inclusion of R1 was slower and larger than the increase induced by inclusion of R6. In both cases, when PACAP38 was applied after the induction of potentiation, no additional increase was observed. This suggests that RACK1 is required for enhancement of NMDAR currents by PACAP38. However, these results introduce the conundrum that the signaling could be either Fyn or Src mediated. To resolve this issue, we used the Src-specific inhibitory peptide Src(40 -58), which was applied through the patch pipette along with either R1 or R6. In both cases, inclusion of 25 g/ml Src(40 -58) blocked the ability of the RACK1 peptides to induce an increase in NMDA peak currents. This implies that for both circumstances Src is mediating the ability of PACAP38 to modulate NMDAR activity.
Discussion
The mechanism whereby PACAP modulates NMDARs is poorly understood but is of great interest because these receptors are essential in development, synaptic plasticity, and excitotoxicity (McBain and Mayer, 1994; Dingledine et al., 1999) . Here we have shown that PACAP38 increases Schaffer collateral EPSC NMDA s, miniature EPSC NMDA s in cultured hippocampal neurons, and peak NMDAR currents in isolated CA1 hippocampal neurons. All of these responses to PACAP38 were blocked when the Src inhibitor peptide was included in the patch electrode. Furthermore, the response in isolated neurons was blocked by the antagonist PACAP(6 -38), confirming that this signal was mediated by the PAC 1 receptor. Additionally, signaling through heterotrimeric G-proteins was confirmed using GDP-␤-S, a competitive inhibitor for the GTP binding site. The large reduction in the response to PACAP seen in CA1 neurons taken from PLC␤1 knock-out mice, without any change in the production of cAMP, strongly suggests that PACAP enhances NMDARs via G␣ q and not G␣ s . A major role for PKC signaling in this pathway is further implicated because bisindolymaleimide I, an inhibitor of PKC, blocks the PACAP38 effect.
PKC enhances NMDARs in CA1 neurons through the activation of the nonreceptor tyrosine kinases CAK␤ (Pyk2) and Src (Lu et al., 1999; Huang et al., 2001; Benquet et al., 2002; Gerber, 2002; Alier and Morris, 2005; Grishin et al., 2005) . Here we have shown that applications of recombinant CAK␤ or Src induce an increase of NMDAR peak currents that occlude the effect of PACAP38. PACAP38 also increased phosphorylation of endogenous Src at tyrosine 416 indicative of kinase activation. A functionally dominant-negative form of recombinant CAK␤, CAK␤ 457A, and the Src specific inhibitor Src(40 -58) both blocked the potentiation of NMDA currents by PACAP38. Therefore, our results are consistent with PAC 1 R activation enhancing NMDAR activity via stimulation of the sequential signaling by PKC/CAK␤/Src.
Our results are in accordance with previous studies in which PACAP38 enhanced NMDAR activity in the hippocampal CA1 region (Wu and Dun, 1997; Roberto and Brunelli, 2000; Yaka et al., 2003) . However, Liu and Madsen (1997) proposed that PACAP38 modulates NMDARs by a direct effect of PACAP38 on the NMDAR, possibly acting through the glycine binding site. Contrary to this finding, we have shown that low concentrations of PACAP38 act through the PAC 1 receptor to enhance NMDA currents. PACAP38 at high concentrations (100 nM) may directly inhibit NMDARs, although we found no dependency on the concentrations of glycine suggesting that this is not via an interaction with the glycine binding site.
PACAP has been reported to cause the release of neurotrophic factors from astrocytes (Pellegri et al., 1998) . Release of neurotrophic factors, such as BDNF, likely contributes to the neuro- Figure 7 . Binding of Src to the scaffolding protein RACK1 is required for PACAP modulation. A, Inclusion of 100 M R1 in the patch pipette caused an increase in normalized NMDA peak currents. In a separate group of cells, the external application of 1 nM PACAP38 caused no additional enhancement of NMDA peak currents. When the selective Src kinase peptide inhibitor Src(40 -58) at 25 g/ml was included in the patch along with 100 M R1, the potentiation of peak currents was severely attenuated: R1 alone, 147 Ϯ 9%, n ϭ 7; R1 plus PACAP38, 150 Ϯ 12%, n ϭ 7; R1 plus Src(40 -58), 112 Ϯ 9%, n ϭ 9; data obtained at 25 min of recording. *p Ͻ 0.05 versus R1 plus Src(40 -58), ANOVA followed by post hoc Tukey's test. The black bar indicates application of PACAP38. B, Inclusion of 100 M R6 resulted in a similar pattern as that for experiments with the R1 peptide: R6 alone, 137 Ϯ 8%, n ϭ 7; R6 plus PACAP38, 138 Ϯ 6%, n ϭ 6; R6 plus Src(40 -58), 112 Ϯ 6%, n ϭ 6; data obtained at 25 min of recording. *p Ͻ 0.05 versus R6 plus Src(40 -58), ANOVA followed by post hoc Tukey's test. The black bar indicates application of PACAP38.
protective effects of PACAP, but these factors may also act as regulators of NMDAR activity themselves (Jarvis et al., 1997) . Furthermore, Roberto and Brunelli (2000) suggest that PACAP may mediate its effects presynaptically by altering muscarinic activity. However, the use of isolated CA1 neurons as well as intracellular applications of agents via the patch pipette have allowed us to determine the major signal components responsible for the postsynaptic regulation of NMDARs by PAC 1 Rs.
Previously, a role for Fyn, a related Src family kinase, was proposed in PACAP38 signaling (Yaka et al., 2003) . In this proposed model, Fyn is inhibited by its binding to RACK1, and PKA stimulates translocation of RACK1 to the nucleus, freeing Fyn to phosphorylate NMDARs (Yaka et al., 2002 (Yaka et al., , 2003 . However, Src also binds to RACK1 (Chang et al., 1998 (Chang et al., , 2001 , and RACK1 reduces of the activity of both tyrosine kinases (Chang et al., 1998; Yaka et al., 2002) . In isolated CA1 neurons, introduction of peptides homologous either to the binding site on RACK1 for Fyn (R1) or Src (R6) increased peak NMDA currents presumably by disinhibiting these kinases. Applications of PACAP38 on top of this enhancement had no additional effect, suggesting that the disruption of this binding disrupts the signaling induced by PACAP38. To ensure that it was the release of Src that was mediating the response to the peptides, the Src inhibitory peptide Src(40 -58) was included in the patch pipette along with the RACK1 peptides. Inclusion of the Src-selective inhibitor abolished the increase of current seen when R1 or R6 was applied to the cells. The inhibitor peptide Src(40 -58) mimics the unique region of Src and not regions of any of the other Src family tyrosine kinases. Most importantly, Src binds by its unique domain to an identified region of ND2, a protein that serves as the major scaffolding protein for Src at hippocampal synapses (Gingrich et al., 2004) . Other Src kinases, including Fyn, do not. Indeed, Src(40 -58) acts by displacing Src from ND2, and this inhibitor does not alter the association of ND2 with NMDARs, nor does it alter the catalytic activity of Src (Gingrich et al., 2004) . Our results suggest that the actions of Fyn kinase on NMDARs depends on the subsequent activation of Src. Therefore, as RACK1 binds activated PKC, Fyn, and Src, it may act as a hub (Ron and MochlyRosen, 1994; Chang et al., 1998) in which CAK␤ can be activated by PKC in the correct spatial arrangement to activate Src.
This study contributes to the growing body of evidence demonstrating a role for PACAP modulation of NMDAR activity. Indeed, many physiological roles attributed to NMDA are also attributed to PACAP. One role for NMDARs is development (Arimura et al., 1994; Jaworski and Proctor, 2000) . Similarly, PACAP expression also has an essential role in development, and this is most clearly seen in PACAP Ϫ/Ϫ animals, which display high mortality rates soon after birth (Hashimoto et al., 2000; Sauvage et al., 2000; Gray et al., 2001) . Furthermore, both PACAP and NMDARs play a role in learning and memory. In the CA1 region of the hippocampus, increased NMDAR activity and increased Ca 2ϩ entry through the receptor is required for the formation of LTP (Collingridge and Bliss, 1995) . It is believed that LTP represents the cellular basis for learning and memory. Because PACAP38 can increase NMDAR activity, it is not surprising that PACAP and its signaling pathways have been linked to learning and memory. In experiments using hippocampal slices, PACAP38 has been shown to increase field EPSPs (Roberto and Brunelli, 2000; Yaka et al., 2003) . This change in synaptic strength by PACAP38 is thought to contribute to the long-term changes associated with learning and memory. Indeed, this paper shows that PACAP38 can increase the amplitude of NMDA currents in hippocampal slice. A role for PACAP in learning and memory clearly exists, but experimental results suggest that this role may be complex. Experiments with PAC 1 R Ϫ/Ϫ mice have shown learning deficits in traditional hippocampal-dependent tasks, such as associative memory tasks, whereas hippocampaldependent declarative memory tests, such as the Morris water maze, are unaffected (Sauvage et al., 2000; Otto et al., 2001) . The lack of effect in declarative learning might be explained by VPAC 1 and VPAC 2 receptors compensating for the lack of PAC 1 Rs. Use of PACAP Ϫ/Ϫ mice in learning paradigms would assist in clarifying the role of PACAP in learning and memory. However, as mentioned previously, PACAP Ϫ/Ϫ mice display high mortality rates (Hashimoto et al., 2000; Sauvage et al., 2000; Gray et al., 2001) . PACAP Ϫ/Ϫ mice also display aberrations to psychomotor behavior, including increased ambulation, explosive jumping, decreased anxiety, and altered mating behavior, which can be relieved with antipsychotics (Hashimoto et al., 2001 ). Interestingly, transgenic mice that express only a small percentage of the NR1 subunit exhibit many similar behaviors, also relieved by the typical antipsychotic haloperidol and the atypical antipsychotic clozapine (Mohn et al., 1999) . These NR1 transgenic mice provide evidence for the hypoglutamatergic model of schizophrenia in which decreased glutamate activity, especially decreased NMDAR activity, contributes to schizophrenic symptoms . This hypothesis is supported by evidence that administration of the NMDAR antagonist phencyclidine to humans causes both positive and negative symptoms associated with schizophrenia . Similarities between these two animal knock-outs suggest that deficits in PACAP and the PACAP receptor systems could contribute to the symptoms associated with schizophrenia. This forms an interesting but as of yet untested hypothesis.
In summary, we have shown that PACAP38 mediates an increase of NMDA currents via a PKC signaling pathway. Intermediates of this pathway include PLC␤1, Ca 2ϩ , CAK␤, and Src. Furthermore, the scaffolding protein RACK1 is required for this pathway, by binding Src. This pathway does not require PKA and as such represents a novel pathway for the mediation of PACAP38-induced changes in NMDA activity. The link between PACAP and NMDAR systems is strengthened by our results suggesting that PACAP may be involved in many of the physiological roles attributed to NMDARs.
